Human NSCLC cell lines were obtained by the American Type Culture Collection (ATCC, Manassas, Virginia, USA) and were cultured in
RPMI-1640 (Sigma-Aldrich) medium which was supplemented with 10%
foetal bovine serum (FBS; Life Technologies, Gaithersburg, Maryland, USA) in a humidified atmosphere with 5% CO
2. The identity of cell lines was confirmed by human STR testing (ATCC). Selumetinib (MEK-I, AZD6244) and
atezolizumab were purchased from Selleck Chemicals, Munich, Germany. Epacadostat was provided by Incyte Biosciences International S.a.r.l.
Primary antibodies for western blot analysis against phospho-MEK, MEK,
phospho-MAPK44/42,
MAPK44/42,
PD-L1, Ido-1,
CTLA4, LAG-3, TIM-3 and
MHC-I were obtained from Cell Signaling Technology; the following secondary antibodies from Bio-Rad were used:
goat anti-rabbit IgG,
rabbit anti-mouse IgG and
monoclonal anti-α tubulin antibody from Sigma Chemical Co.
Della Corte C.M., Ciaramella V., Ramkumar K., Vicidomini G., Fiorelli A., Nardone V., Cappabianca S., Cozzolino I., Zito Marino F., Di Guida G., Wang Q., Cardnell R., Gay C.M., Ciardiello D., Martinelli E., Troiani T., Martini G., Napolitano S., Wang J., Byers L.A., Ciardiello F, & Morgillo F. (2022). Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. Journal of Translational Medicine, 20, 541.